Daly Jason B. sold $3.8M of AMRX
Daly Jason B. (EVP, Chief Legal Officer) sold 216,613 shares of Amneal Pharmaceuticals, Inc. (AMRX) at an average of $17.41 ($17.40–$17.70, $3.77M total) across 2 trades over 2026-08-11 to 2026-08-12.
How this was made
The 30-second read
Why it matters
The only new information is the insider sale size, price range, and timing; it does not include earnings, guidance, clinical, or regulatory developments.
Market read
Traders may briefly reassess sentiment around AMRX, but the filing is not a fundamental catalyst.
What to watch
The article notes no pre-arranged 10b5-1 plan, which can increase interpretive noise, but the disclosure still lacks any link to company performance or forward guidance.
Background
The article is an SEC Form 4 insider transaction disclosure for Amneal Pharmaceuticals, Inc.
Ticker impact
SEC Form 4 shows AMRX EVP and Chief Legal Officer Daly sold 216,613 shares for about $3.77M at $17.40 to $17.70.
Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.
The filing is primary-source and time-stamped, but it is an insider transaction without accompanying guidance, operational updates, or regulatory/financial events.
Market effects
Minimal; insider selling in a single pharma name rarely changes sector risk premia without additional news.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or scheduled liquidity needs, so the signal may be weak.
Key entities
- issuerAmneal Pharmaceuticals, Inc.
Subject of the Form 4 insider sale by its EVP and Chief Legal Officer.
- insiderDaly Jason B.
EVP, Chief Legal Officer who sold 216,613 shares in two trades.
